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Retroperitoneal massAbstract Bleeding is a common problem during resection of a retroperitoneal mass. Massive
bleeding may occur in case of injury of an adjacent major vessel or organ. This case report describes
a successful anesthetic management of a patient with 10 l of blood loss within three hours surgery.
A 44-year-old woman who underwent an operation for resection of a retroperitoneal mass, went to
a hypovolemic shock, due to acute life-threatening intra-operative bleeding, and was successfully
rescued with a combination of measures, including control of surgical bleeding, supportive treat-
ment with rapid ﬂuid infusion, massive transfusion of blood products and administration of intra-
venous vasoactive agents for maintaining tissue perfusion and oxygenation, utilizing intraoperative
autologous blood salvaged via cell saver, as well as prevention and treatment of complications. The
patient received a total of 22 units of Packet Red Blood Cells (PRBCs), 18 units of Fresh Frozen
Plasma (FFP), 10 units of cryoprecipitate, 3750 ml of her own salvage blood. Postoperatively, she
was transferred to the intensive care unit (ICU) with mechanical ventilator support, where she
received another 5.4 units of FFP, 10 units of cryoprecipitate. The patient developed features of
early acute lung injury such as fever and hypoxemia, and was managed successfully with mechanical
ventilator support for a few days. At a three-month follow-up, the patient was doing very well. This
paper explores the pathogenesia, implications, prevention and treatment of the transfusion-associ-
ated complications such as acidosis, hypothermia, electrolyte abnormalities, and transfusion-related
acute lung injury (TRALI). Particular attention is given to the prevention of secondary coagulop-
athy of the patient requiring massive blood transfusion. This case study presents a good reference
for similar anesthetic scenario in the future.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Case presentation
A 44-year-old normotensive, nondiabetic woman with a retro-
peritoneal mass, which was identiﬁed by Computed Tomogra-
phy (CT) scan of abdomen, during her health screening two
208 X. Zhu et al.weeks ago, was admitted to our hospital for resection of the
retroperitoneal mass.
She had a medical history of schizophrenia over 23 years,
for which she was still taking an antipsychotic drug,
Clozapine, 3 tablets daily, and no other past medical history
of illness.
Pre-anesthetic evaluation did not reveal any abnormal ﬁnd-
ings. She had a body weight of 71 kg, height of 159 cm, heart
rate (HR) of 70 beats/minute (bpm), and blood pressure (BP)
of 130/80 mmHg. Her preoperative laboratory tests showed
hemoglobin (Hb) of 109 g/L, hematocrit (Hct) of 31%, platelet
(Plt) count of 195 · 109/L, prothrombin time (PT) of 10.9 s,
international normalized ratio (INR) of 0.89 and activated
partial thromboplastin time (aPTT) of 20.9 s.
On arrival in our operating room, she had BP of
140/80 mmHg with HR of 88 bpm. An 18-gauge peripheral
intravenous (IV) line was placed on her right forearm and kept
open with lactated Ringer’s solution, and standard monitor-
ing, including non-invasive blood pressure (BP), 3-lead ECG
and Pulse oximetry (SpO2), was given.
Surgical resection of a retroperitoneal mass was performed
under general anesthesia combined with epidural anesthesia.
After induction of general anesthesia, a radial arterial line
was placed for continuous monitoring of arterial blood pres-
sure (ABP) and collection of arterial blood for blood gas anal-
ysis during operation, and a central venous catheter was placed
into the right internal jugular vein.
Surgery revealed that the retroperitoneal mass, located
between abdominal aorta and left renal hilum, adhered to left
renal hilum. In the course of the mass being separated from the
left renal hilum, the patient developed signiﬁcant bleeding. At
the time when blood loss amounted to 500 ml, expedited infu-
sion of lactated Ringer’s solution and 6% hydroxyethyl starch
were made with simultaneous applying for 3 units PRBCs
from blood bank. As result of the sustained severe hemorrhage
in the surgical site, the patient required massive transfusion of
blood products, so as to meet the need of maintaining her cir-
culating blood volume. But, the needed blood products were
unable to be timely issued and delivered, the patient was
becoming hemodynamically instable over time. When the
amount of blood loss within half an hour reached to
3000 ml, her ABP decreased abruptly to 52/30 mmHg with
HR of 42 bpm. She was emergently given 10 lg of epinephrine
via the right internal jugular vein, followed by a continuous
infusion of epinephrine for additional hemodynamic support,
prompt adjustment of the dosage of epinephrine to try to
maintain a mean arterial blood pressure (MAP) of 65 mmHg
or above. Meanwhile, some rescue actions were taken, includ-
ing the following:
 Requesting the surgeon to stop operation immediately and
exerting direct pressure on the area of bleeding.
 Expedited infusion of ﬂuids and transfusion of blood prod-
ucts (PRBCs and FFP).
 Established an additional wide bore venous access via left
internal jugular venous.
 Pre-warming of resuscitation ﬂuids and blood products,
and using of patient warming device to prevent the patient
from hypothermia.
 Emergency arterial blood gas analysis (ABG) demonstrat-
ing a PH of 7.28, ionized calcium of 0.97 mmol/L, hemoglo-
bin of 77 g/L. Made decision to use intraoperative autologous blood sal-
vage (the patient’s tumor properties were not clear, the
intraoperative salvaged blood possibly contained malignant
cells. But in life-saving situation with the consent of the sur-
geon, it could be utilized to support the patient’s vital
signs).
After the treatments, the patient’s MAP rose temporarily
up to P65 mmHg. As such, the surgeons could continue to
perform the surgery, and look for the active bleeding spot. It
was found that the source of bleeding was the lacerated left
renal vein and there was unfortunately no way to repair. So,
the left nephrectomy had to be performed, with the consent
of the patient’s family. And then, the retroperitoneal mass
was removed successfully, after which the bleeding gradually
reduced and eventually stopped. During this period, the oper-
ation had to be stopped several times, due to bleeding with the
patient’s BP declining rapidly.
Overall, total amount of blood loss of the patient within 3 h
was 10.01 L. In the course of 8 h surgery, she received total 22
units of PRBCs, 18 units of FFP, 10 units of cryoprecipitate,
3750 ml of autologous salvaged blood via a cell saver,
4000 ml of crystalloids (lactated Ringer’s solution and normal
saline) and 2500 ml of colloid (hydroxyethyl starch), according
to her physiologic parameters & laboratory testing reports. She
was also given 4 g intravenous calcium gluconate, 3 g potas-
sium chloride and some units of insulin, to correct the electro-
lyte abnormalities and hyperglycemia, depending on the results
of repeated ABG analysis. Additionally, 4 mg intramuscular
penehyclidine hydrochloride (PHC), a new anti-cholinergic
drug, was given to her, for possibly improving microcircula-
tion, depressing stress response, and so on.
After the above treatments, she gradually was hemody-
namic stable. When her hemodynamic was still maintained
on stable state without any vasopressor support, 10 mg of
furosemide was intravenously injected. Thus, she had
2600 ml of urine output during the course of surgery. Postop-
eratively, she was shifted to the intensive care unit (ICU) with
mechanical ventilator support, where she received another 5.4
units of FFP and 10 units of cryoprecipitate, as well as 10 g
albumin to correct the hypoproteinemia, so as to increase
her osmotic pressure and alleviate her systemic edema.
In ICU, guided by repeated monitoring of ABG and hae-
matological tests, she was extubated on the third day after
operation. She was shifted out of ICU to general ward, contin-
ued with supportive care. Her last report in ICU showed Hb of
97 g/L, Hct of 27%, Plt counts of 60 · 109, and PT/INR,
APTT within normal limits.
Throughout the operative period and ICU stay, the labora-
tory examinations (see Table 1) and ABG analysis (see Table 2)
were regularly monitored.
The patient had been recovering quite well. No infection of
incisional wound was observed. After another 12 days in the
ward she was discharged. The pathological examination of
the mass revealed a spindle cell tumor, which was a benign
tumor. At the three-month follow-up, she was doing all well.2. Discussion and literature review
Hemorrhagic shock is a severe clinical syndrome, produced by
rapid and massive blood loss, which may lead to hemodynamic
Table 1 Laboratory parameters.
Date/time Hb (g/L) Plt (109/L) PT/INR (s) aPTT (s) Fib (g/L) D-dimer Creat (mmol/L) Alb (g/L)
Preop 109 195 10.9/0.89 20.7 2.69 74 51 38.3
D1@Intraop 16:13 95 Nil 19.3/1.57 64.8 0.84 3735 Nil Nil
21:22@ ICU 143 42 16.3/1.33 32.8 1.18 3086 61 18.3
D2@ ICU 8:40 122 50 13.1/1.07 24 2.49 673 102 25.9
D2 19:10 99 58 14.7/1.2 27.9 2.61 656 Nil Nil
D3@ ICU 8:22 100 51 Nil Nil Nil Nil 122 35.3
D4@ ICU 8:25 95 61 12.7/1.03 24.3 4.38 1547 Nil Nil
D5@Ward 104 114 Nil Nil Nil Nil 92 37.4
D8@Ward 112 202 Nil Nil Nil Nil 78 35.7
Hb = hemoglobin; Plt = platelet; PT = prothrombin time; aPTT = activated partial thromboplastin time; INR= international normalized
ratio; Fib = ﬁbrinogen; Creat = creatinine; Alb = albumin.
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cellular hypoxia, organ damage, and even death. One of life-
saving treatments of hemorrhagic shock is massive transfusion
(MT). MT is commonly deﬁned as the transfusion of at least
10 units PRBCs within 24 h to an individual patient or the
transfusion of more than one blood volume in 24 h (note that
adult blood volume is approximate 70 ml/kg) [1–3]. However,
it is a non-physiologic state and can be associated with many
complications, such as acidosis, hypothermia, coagulopathy,
electrolyte abnormalities, citrate toxicity, and transfusion-
related acute lung injury (TRALI).
2.1. Complications related to massive transfusion
2.1.1. Acidosis
In patients with hemorrhagic shock, acidosis often results from
tissue hypo-perfusion and hypothermia. And the acidosis is
worsened by massive transfusion of acidic stored blood prod-
ucts, because the pH of PRBCs decreases from 7.4 to 6.9
almost immediately after storing and even falls to as low as
6.7 after 3 weeks [4].
Furthermore, acidosis may impair almost all essential parts
of the coagulation process [5,6]. Platelets will change their
structure and shape at pH below 7.4 [6,7]. Clotting factors
are enzymes whose activity will reduce 50–90% with a decrease
in pH from 7.4 to 7.0 [8–10]. Thus, thrombin generation, which
is the primary engine of hemostasis, is profoundly inhibited by
acidosis. Moreover, acidosis leads to increase in the degrada-
tion of ﬁbrinogen [5,8], which further worsens the coagulopa-
thy. Thus, in case of severe hemorrhage, buffering between
physiologic pH values is recommended as the arterial
pH > 7.2.
The citrate, which existed in stored blood products, will be
metabolized to bicarbonate. Therefore, the correction of aci-
dosis with sodium bicarbonate in patients requiring MT,
should be used as a temporary measure, only in patients with
severe metabolic acidosis and hemodynamic instability. In our
case study, when the ABG analysis revealed the pH value of
7.17, 125 ml of sodium bicarbonate was infused. If needed
again, should depend on the results of ABG analysis. How-
ever, once adequate tissue perfusion is restored, the citrate
and lactate are converted to bicarbonate in the liver, in addi-
tion to our patient showed a good renal function with ade-
quate urine output, and was maintained on mechanical
ventilator support. So, the acidosis resolved easily (see Table 2).2.1.2. Hypothermia
Hypothermia, deﬁned as a situation with core body temper-
ature <35 C [11], occurs frequently in patients requiring
MT. There are multiple factors in trauma patients that con-
tribute to hypothermia, including infusion of cold ﬂuids and
blood products, opening of body cavities, decreased heat
production, and impaired thermoregulatory control. Infusion
of cold ﬂuids and stored blood products is a well-known
cause of hypothermia. Blood products are normally stored
between 1 C to 6 C, and thus rapid transfusion of large
amount of such blood products will lead to hypothermia
easily.
Hypothermia can reduce clotting factor activity. There is a
10% drop in clotting factor activity for each 1 C drop in
temperature and there is a more than 50% reduction in nor-
mal factor activity at temperature below 33 C [7,11,12]. It
can also alter platelet function (signiﬁcant platelet dysfunc-
tion is observed below 34 C [9,12]), inhibits activity of
enzyme and causes induction of ﬁbrinolysis [8,10,12]. But
these effects are reversible with normalization of body
temperature.
Therefore, it is important to prevent hypothermia and
reduce the risk of hypothermia-induced coagulopathy. Actu-
ally, hypothermia in patients requiring MT can be avoided
by the following:
 Removing wet clothing.
 Covering the patient to avoid additional heat loss.
 Increasing the room temperature.
 Surface warming the patient with heating blankets and
heating lamps.
 Using of heated and humidiﬁed inspired gases for
ventilators.
 Using blood and ﬂuid warmers for all ﬂuids administered.
Although simple, these interventions may be lifesaving, and
should be implemented as early as possible in any patient with
hemorrhagic shock. In our case, patient was prevented from
hypothermia by pre-warming of all administered ﬂuids and
cold blood products, surface warming via patient warming
devices, and increasing the operating room temperature.
Because the monitor of body temperature is not yet widely
available in our operating room, we monitored her body tem-
perature only by frequently touching and feeling her limbs to
ensure them keeping warm up.
Table 2 Arterial blood gas analysis in clinical course.
Date Time PH PaO2 PaCO2 BE Lac. Glu. Ca
2+ K+ Hb Major clinical event
D1 Intraop: 12:34 7.28 92 48 4.1 0.9 10 0.97 3.6 77 Bloodloss 3000 ml, PRBC 8U, low-dose
epinephrine
13:14 7.23 138 44 92 1.5 13.9 0.88 3.8 81 Use intraop blood salvage, PRBCs 4U, FFP
800 ml
14:31 7.3 306 45 4.3 4.1 16.9 0.85 2.8 81 Identiﬁed the lacerated left renal vein as the source
of bleeding
15:13 7.2 105 49 8.8 5.7 19.4 0.71 3.0 98 Left nephrectomy and complete resection of the
mass, PRBCs 6U,FFP 500 ml
16:01 7.17 294 44 12.5 6.8 22 0.74 2.8 95 Urine output 200 ml, stopping infusion
epinephrine
17:30 7.11 219 46 14.9 9 20 0.68 2.9 95 Frusemide10 mg, PRBCs 4U, FFP 500 ml, Cryo
10U
ICU: 21:22 7.43 93 23 9 7.2 10.9 0.85 3.4 14 Urine output 2600 ml (intraop), FFP 540 ml, Cryo
10U
D2 ICU: 0:20 7.33 124 33 8.5 6.6 8.3 0.91 3.9 13.3 Spontaneous breathing and ventilator support
PEEP 8 cm H2O FiO2 40%
6:43 7.51 76 29 0.1 3.4 7.4 0.9 4.3 12.2 Infusion Alb 10 g, anti-infection
13:04 7.46 91 33 0.3 1.2 7.5 0.96 3.2 11.5 T38.3 C
18:35 7.44 88 34 1.02 1.6 8.2 1.02 3.3 10.4
D3 ICU: 1:59 7.45 95 35 1.03 0.8 7.7 0.98 3.2 10.4 Spontaneous breathing and ventilator support
FiO2 40%
6:09 7.49 105 32 0.3 0.8 7.9 1.02 3.4 10.4 T38.7 C, anti-infection
12:19 7.45 111 35 0.3 0.6 6.2 1.03 3.2 101
17:42 7.46 107 35 1.1 0.5 6.2 1.03 3.2 101
23:52 7.47 86 33 0.3 0.5 5.7 0.99 3.2 97 On room air
D4 ICU: 6:52 7.47 111 32 0.4 0.5 5.6 0.99 3.2 97 T 38 C, anti-infection, FiO2
12:09 7.48 111 35 2.6 0.5 5.7 1.03 2.9 11.2 Post extubation, back to ward
BE = base excess; Lac = lactic acid; Glu = glucose; FiO2 = fraction of inspired oxygen; PEEP= positive end-expiratory pressure;
Cryo = cryoprecipitate; FFP = fresh frozen plasma; PRBCs = packet red blood cells.
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Coagulopathy related to massive transfusion is multifactorial
[13], including the dilution of clotting factors, consumption
of clotting factors, and hyperﬁbrinolysis [12,14]. Furthermore,
as mentioned above, the acidosis, hypothermia and coagulop-
athy were known to be the lethal triad [10], which worsen hem-
orrhage and transfusion requirements for patients with
hemorrhagic shock.
We usually began resuscitation with crystalloids and col-
loids, such as normal saline, lactated Ringer’s solution and
hydroxyethyl starch (HES). Although it may restore part of
the circulating volume, the induced dilutional anemia and
coagulopathy are described [9,15]. In addition to its use acti-
vating inﬂammatory cascades, leads to cellular swelling, acido-
sis, and organ dysfunction [16], which may be associated with
increased mortality [17]. Thus, large-volume resuscitation with
crystalloids should be avoided. However, the clinical effect of
hydroxyethyl starch (HES) on coagulation remains unclear
[15,18]. A study demonstrated that HES administration may
promote a dose-dependent coagulopathy [19]. Therefore, if
colloids are administered for resuscitation, the dosage should
be within the prescribed limits.
Furthermore, massive transfusion of blood products such
as RBC, FFP and PLT may also cause dilutional coagulopathy
since these blood products are stored in anticoagulation solu-
tions, leading to a decrease in concentrations of clotting fac-
tors to approximately 60% [18].
So, FFP and platelets should be given earlier to patients
requiring massive transfusion. However, the optimal ratio ofPRBCs, FFP and platelets is not known. Based on a massive
transfusion protocol (MTP), the optimal ratio is recommended
to be likely close to 1:1:1 [20,21]. Although, each unit of FFP
contains 0.5 g of ﬁbrin, hemorrhage requiring MT may still
lead to consumptive and dilutional hypoﬁbrinogenemia
[22,23]. Coagulopathy worsens when serum ﬁbrinogen level
falls below 100 mg/dl. In our case, during massive transfusion,
the patient’s ﬁbrinogen level in plasma was monitored and
documented with 84 mg/dl, thereafter 10 units of pooled cryo-
precipitate was transfused to correct the hypoﬁbrinogenemia.
Despite enhanced understanding of the mechanisms under-
lying coagulopathy associated with MT, early recognition of
coagulopathy remains an important clinical problem. Routine
laboratory tests, such as PT/INR and aPTT have several lim-
itations in clinical emergent situation. They are included that:
(1) the time taken from blood sampling to test result is usually
45 min, (2) the coagulation tests are determined from plasma
not whole blood, (3) no information regarding platelet func-
tion is provided, (4) the time for clot formation provides no
information regarding clot strength of subsequent ﬁbrinolysis.
Therefore, these limitations weaken the practicality and possi-
bly the clinical relevance of PT/INR and aPTT in the clinical
emergent situation.
However, point of care monitoring devices that evaluate the
viscoelastic properties of whole blood, like thromboelastogra-
phy (TEG), may overcome the above limitations of routine
laboratory coagulation tests in the perioperative setting. It
allows whole blood to be analyzed at bedside, thus faster
turnaround times. Furthermore, it may be used to quantify
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tion [9,24]. Recently, a study had showed that 82% of trauma
patients requiring MT received insufﬁcient amounts of FFP
and Platelets when managed by ‘‘blind’’ transfusion practices
[14,25]. Moreover, it has been shown that hemostatic resuscita-
tion guided by TEG in operating room may reduce transfusion
requirement and blood loss [26]. Unfortunately, it is not yet
available in our operating room.2.1.4. Electrolyte abnormality
(1) Hypocalcemia
Stored blood products are anti-coagulated with citrate,
which binds ionized calcium. Each unit of PRBCs contains
about 3 g of citrate. Although the healthy adult liver can clear
this dose of citrate in approximately 5 min [9,12], transfusion
rate higher than 1 unit every 5 min or impaired hepatic func-
tion may lead to hypocalcemia [12]. Calcium is necessary for
clotting activity, myocardial contraction, and vasomotor tone.
The level of arterial blood ionized calcium below 0.8–
0.9 mmoL/L leads to coagulopathy and impaired cardiovascu-
lar function [6,12]. Therefore, it is critically important to fre-
quently monitor ionized calcium concentration and keep it
within the normal range, during massive transfusion. Intrave-
nous calcium administration is the appropriate treatment of
ionized hypocalcemia. In our case, patient received total 4 g
of intravenous calcium gluconate, guided by a serial monitor-
ing of the ionized calcium concentrations.
(2) Hyperkalemia and hypokalemia
Hyperkalemia may occur in patients requiring massive
transfusion, due to the high extracellular potassium concentra-
tion in stored PRBCs [12]. Additionally, it also may be as
result of oliguria (due to hypovolemia) and acidosis (results
from tissue hypoperfusion and massive infusion of the acidic
stored PRBCS). However, it did not occur in our patient.
In contrast, hypokalemia was presented in our patient. Its
mechanisms are as followed:
 Dilutional hypokalemia due to massive infusion of the
potassium-poor solution, such as crystalloid, colloid, FFP
and platelets.
 In patients with shock, plasma concentration of epinephrine
increases 50-fold and norepinephrine level increases 10-fold
[27]. Moreover, the circulating catecholamine leads to
movement of potassium from extracellular ﬂuid into cells,
thus lower serum potassium.
 Continuous infusion of exogenous epinephrine leads to the
potassium in plasma shifting into cells.
 Restoration of the transfused red blood cell membrane
ATPase pump, thus allowing potassium to re-enter the
red cells.
 Alkalosis secondary to citrate metabolism to bicarbonate.
Therefore, the serum potassium concentration of patients
requiring MT should be carefully monitored. A number of
studies have demonstrated that hypokalemia has been seen
in more than 50% of surgical patients with massive transfusion
[12]. In our case, although 3 g of potassium chloride was given,
hypokalemia had not been occured until the infusion ofexogenous epinephrine discontinued. Hence, continuous infu-
sion of exogenous epinephrine was thought to be one of the
important causes of the hypokalemia.
2.1.5. Transfusion-related acute lung injury (TRALI)
TRALI is a serious blood transfusion complication character-
ized by the acute onset of respiratory distress, hypoxemia, and
fever. It is deﬁned as acute lung injury that occurs within 6 h
after transfusion [12]. Although transfusion is an independent
risk factor for the development of TRALI, the incidence varies
with type of blood product. In particular, it is a greater risk
after transfusion of FFP or platelet concentrates [27], likely
due to the presence of leukocyte antibodies in transfused
plasma. TRALI is a leading cause of major morbidity and
mortality related to MT [12,28]. Although it is difﬁcult for cli-
nicians to directly prevent TRALI, clinicians need to be alerted
that the adverse effect is dose related. Therefore, blood prod-
ucts must be transfused carefully and appropriately, and exces-
sive transfusion should be avoided. In our case, the patient was
given intraoperative cell salvage to minimize the need for allo-
geneic transfusion, thus reducing risks associated with allogen-
ic blood transfusion. However, our patient developed features
of early ARDS or TRALI (such as the sign of hypoxemia doc-
umented by ABG analysis, mild fever and so on) after transfu-
sion, and was managed with mechanical ventilator support for
3 days in ICU.
2.2. Other aspects of management
2.2.1. Hyperglycemia
Hyperglycemia is especially common in patients with acute
hemorrhagic shock. During early shock, endogenous catechol-
amine levels are signiﬁcantly elevated to maintain end-organ
perfusion in response to hemorrhage [29,30]. However, circu-
lating catecholamine inhibits insulin release and activity, lead-
ing to increased plasma level of glucose. Furthermore,
glucagon is also secreted in response to stress, such as hypovol-
emia, hypoglycemia. Thus, it has been termed stress-induced
hyperglycemia (SIH) and deﬁned as a transient elevation of
plasma glucose level due to the stress of illness. SIH may be
associated with some of the same complications as hyperglyce-
mia in diabetes mellitus, such as poor wound healing and a
higher infection rate, and higher mortality in trauma patients
[31]. However, strict glycemic control and intensive insulin
therapy could improve the survival rate in critically ill patients
[31,32]. In our case, the patient developed a sustained hyper-
glycemia in the course of resuscitation. Although, when
ABG analysis discovered the level of blood glucose
>11.1 mmol/L, continuous infusion of some units of insulin
started, the blood glucose level still transiently reached to
22 mmol/L. However, it was observed that the blood glucose
level gradually decreased and returned to near normal levels,
following the reduction and stopping in dosage of exogenous
epinephrine infusion. Therefore, our ﬁnding suggested that
exogenous epinephrine, needed for additional hemodynamic
support in the course of resuscitation, is an important contrib-
utor to SIH. Epinephrine via a beta-adrenergic- receptor mech-
anism, causes excessive plasma glucagon elevation. Thus, the
continuous infusion of epinephrine for hemodynamic support
may be not appropriate for the patients with hemorrhagic
shock. It may be beneﬁcial on continuous infusion of an
212 X. Zhu et al.alpha-adrenergic-receptor agonist, such as norepinephrine for
hemodynamic support.
2.2.2. Pharmacologic therapy
Anti-cholinergic drugs have been reported in the treatment of
septic shock, and found to have protective effects against sep-
tic shock. In animal experiment, anti-cholinergics may reduce
bio-membrane lipid peroxide, decrease the release of cytokines
and oxyradicals, stabilize bio-membrane, protect the cell struc-
ture, and thus maintain their normal functions [33].
However, traditional anti-cholinergics would increase
HR, and thus resulting in the limitation of their application
in the treatment of shock. Penehyclidine hydrochloride
(PHC) is a new anti-cholinergic drug, which has the charac-
teristics of selectively blocking M-cholinergic receptor
subtype M1 and M3, with little or no effect on receptor
M2, and thus does not accelerate HR. It has been reported
that PHC could signiﬁcantly improve the microcirculation,
shorten the time of shock resuscitation, and possibly reduce
mortality in mice with septic shock [33]. More studies in ani-
mal models [33,34] showed that PHC could also attenuate
renal, cerebral, gastrointestinal ischemia–reperfusion (I/R)
injury, by reducing inﬂammatory response, oxidative stress
and apoptosis.
Moreover, in recent years, several studies have demon-
strated that PHC can be used in the treatment and prevention
the development of ALI [35]. For the patients with ALI/
ARDS, there will be appearing increase of cholinergic recep-
tors density, hypertonia of airway and vascular smooth mus-
cles, airway hyper-responsiveness [36,37], whereas PHC can
lift airway and vascular smooth muscle spasm, inhibit respira-
tory gland secretion and improve cellular oxygenation at an
early stage of ALI [36]. So, PHC is expected to be a potential
choice for ALI management. In our case, patient was empiri-
cally given intramuscular injection of 4 mg PHC for improve-
ment of microcirculation and prevention the development of
ALI. But, at present, mechanical ventilation support is still
the most effective clinical treatment of ALI/ARDS. Our
patient was also supported with mechanical ventilation for
several days in ICU.
2.2.3. Utilizing intraoperative blood salvage
The surgical procedure involving resection of a retroperitoneal
mass for our patient should be considered for implementation
of acute normovolemic hemodilution and cell salvage. But
the former was due to the patient’s starting hemoglobin of
10.9 g/L, later was because of the pathologic type of the
retroperitoneal mass being unclear at that time. Although
there was a possibility of the reinfusion of cancer cells from
the surgical site, as in the unexpected life-threatening
hemorrhage, the intraoperative blood salvage needed to be
used following a risk–beneﬁt analysis. In fact, it has been
shown that a high percentage of patients undergoing cancer
surgery have circulating tumor cells, but only 0.01% to
0.000001% of circulating tumor cells have the potential to
form metastasis [38,39]. Two recently controlled studies [40]
on patients undergoing radical prostatectomy were performed
to evaluate the use of cell salvage, and demonstrated that
massive metastasis did not occur due to the use of cell salvage.
Despite this understanding, the pathologic type of the
retroperitoneal mass of our patient was a benign tumor.3. Conclusions
Acute surgical hemorrhage is a medical emergency with a high
mortality if it leads to acute hypovolemic shock during sur-
gery, hence requiring prompt and effective treatment. Besides,
acute hemorrhagic shock may lead to coagulopathy, due to
consumption and dilution of clotting factors, which may be
worsened by hypothermia and acidosis. Previous sections have
demonstrated some key points in the management of these sit-
uations, including control of bleeding, blood transfusion and
supportive treatments for the maintenance of adequate tissue
perfusion and oxygenation, the correction of hypothermia,
anemia, acidosis and electrolyte abnormalities, and the use of
appropriate blood products including FFP, platelet concen-
trate and cryoprecipitate to correct coagulopathy. Therefore,
in patients with critical bleeding requiring massive transfusion,
repeated monitoring of ABG, frequent assessment of coagula-
tion parameters including platelets count, ﬁbrinogen level, PT
and aPTT, and continuous monitoring of temperature, are
strongly required.
Furthermore, allogenic blood products are immunomodu-
latory, and may result in multi-organ dysfunction. Although,
use of an MTP (massive transfusion protocol) with predeter-
mined ratios of blood products (PRBCs, FFP, and platelets)
may improve patient’s outcomes and reduce allogenic blood
components use, its implementation requires close collabora-
tion among multidisciplinary departments, including the blood
bank, the laboratory, the operating room and ICU, to ensure
the timely delivery of blood products, incorporate serial mon-
itoring of laboratory parameters, and prompt correction of
patient’s physiologic disturbances. In our case study, the
patient required massive transfusion but we didn’t follow
any MTPs strictly, yet the patient recovered well. This may
be due to that the facts we tried our best with the near standard
blood transfusion protocol, in addition, prompt and effective
administration of cell salvage reduced the need for allogeneic
red cell transfusion, minimizing the transfusing-associated
complications.Conﬂict of interest
None.
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